Michele Rhee

Michele Rhee is Head of Global Advocacy Relations and Patient Engagement at Savara Inc. She has nearly two decades of experience engaging with patient communities and leading patient advocacy across biopharmaceutical and nonprofit industries. Michele has built the patient advocacy function as Vice President of Patient Affairs and Advocacy at X4 Pharmaceuticals and Head of Patient Affairs at Enzyvant. Prior to her work at Enzyvant, Michele served as Global and R&D Patient Advocacy Lead at Takeda Oncology, Head of Patient Advocacy at bluebird bio, and Director of both Strategic Initiatives and Program Initiatives at the National Brain Tumor Society. In addition, Michele was appointed to the Massachusetts Rare Disease Advisory Council in 2021 and is a founding board member for Costs of Care, an organization dedicated to helping clinicians and health systems deliver better care at lower cost. Michele received her MPH from Yale School of Public Health and MBA from Yale School of Management.